


**DURECT**[ABOUT](#) | [PRODUCTS](#) | [PIPELINE](#) | [SCIENCE & TECHNOLOGIES](#) | [INVESTORS](#) | [NEWS](#)

TRANSFORMING MEDICINE. RESTORING WELLBEING.

DURECT is a biopharmaceutical company focused on the development of medicines that provide meaningful advances in patient health and wellbeing.

[PIPELINE](#)[LEARN MORE >](#)[INVESTORS](#)[PIPELINE](#) | PHASE 1

DUR-928

An endogenous, orally bioavailable small molecule in development for chronic liver disease and acute organ injury

[SEE HOW IT WORKS](#)

NEWS

DURECT TO PRESENT AT THE RODMAN & RENSHAW GLOBAL INVESTMENT CONFERENCE
September 6, 2016

DURECT CORPORATION ANNOUNCES SECOND QUARTER 2016 FINANCIAL RESULTS AND UPDATE OF PROGRAMS
August 1, 2016

DURECT CORPORATION INVITES YOU TO JOIN ITS SECOND QUARTER 2016 EARNINGS CONFERENCE CALL
July 25, 2016

[VIEW ALL >](#)

REMOXY® ER

A unique long-acting, tamper-resistant formulation of oxycodone based on DURECT's ORADUR® technology.

[LEARN MORE >](#)

© 2000-2016 DURECT CORPORATION

[BUSINESS DEVELOPMENT](#) | [CAREERS](#) | [CONTACT](#) | [LEGAL NOTICE](#) | [PRIVACY POLICY](#)



PRODUCTS



IN DEVELOPMENT >

DUR-928

POSIMIR® (SABER®-
Bupivacaine)

REMOXY® ER (ORADUR®-
Oxycodone)

ORADUR®-Hydromorphone and
ORADUR®-Oxymorphone

ORADUR®-Methylphenidate

RELDAY® (SABER®-Risperidone)

ELADUR® (TRANSDUR®-
Bupivacaine)

SUSTAINED-RELEASE
Ophthalmology Product

COMMERCIAL PRODUCTS

ALZET® Osmotic Pumps

LACTEL® Absorbable Polymers

REMOXY® ER (ORADUR® -Oxycodone)

Product Overview

Based on DURECT's ORADUR technology, REMOXY ER is a unique long-acting formulation of oxycodone designed to discourage common methods of tampering associated with opioid misuse and abuse. It is intended for patients with moderate-to-severe chronic pain.

When taken as prescribed, opioid analgesics allows individuals suffering from chronic pain to sufficiently control their pain and resume many of their daily activities. However, this class of drugs may be abused, misused, and diverted, which has led to a major public healthcare crisis.

Potential Benefits



Commercial Opportunity



Current Status



Commercial Rights



[Explore REMOXY ER publications >](#)


[Learn more about ORADUR abuse-deterrent technology >](#)

There are risks and uncertainties associated with our business. Please see our most recent SEC filings (10-K or 10-Q) for a complete description of these risks and uncertainties, which are incorporated herein by reference.





PRODUCTS



IN DEVELOPMENT >

DUR-928

POSIMIR® (SABER®-
Bupivacaine)

REMOXY® ER (ORADUR®-
Oxycodone)

ORADUR®-Hydromorphone and
ORADUR®-Oxymorphone

ORADUR®-Methylphenidate

RELDAY® (SABER®-Risperidone)

ELADUR® (TRANSDUR®-
Bupivacaine)

SUSTAINED-RELEASE
Ophthalmology Product

COMMERCIAL PRODUCTS

ALZET® Osmotic Pumps

LACTEL® Absorbable Polymers

REMOXY® ER (ORADUR® -Oxycodone)

Product Overview

Based on DURECT's ORADUR technology, REMOXY ER is a unique long-acting formulation of oxycodone designed to discourage common methods of tampering associated with opioid misuse and abuse. It is intended for patients with moderate-to-severe chronic pain.

When taken as prescribed, opioid analgesics allows individuals suffering from chronic pain to sufficiently control their pain and resume many of their daily activities. However, this class of drugs may be abused, misused, and diverted, which has led to a major public healthcare crisis.

Potential Benefits

- Effective long-term pain control with the convenience of twice-daily dosing
- Proprietary formulation with several properties designed to deter abuse by the most common methods (snorting, smoking, injecting, chewing, and dissolving in drinks)

Commercial Opportunity



Current Status



Commercial Rights



[Explore REMOXY ER publications >](#)

[Learn more about ORADUR abuse-deterrent technology >](#)

There are risks and uncertainties associated with our business. Please see our most recent SEC filings (10-K or 10-Q) for a complete description of these risks and uncertainties, which are incorporated herein by reference.





PRODUCTS

IN DEVELOPMENT >

DUR-928

POSIMIR® (SABER®-
Bupivacaine)

REMOXY® ER (ORADUR®-
Oxycodone)

ORADUR®-Hydromorphone and
ORADUR®-Oxymorphone

ORADUR®-Methylphenidate

RELDAY® (SABER®-Risperidone)

ELADUR® (TRANSDUR®-
Bupivacaine)

SUSTAINED-RELEASE
Ophthalmology Product

COMMERCIAL PRODUCTS

ALZET® Osmotic Pumps

LACTEL® Absorbable Polymers

REMOXY® ER (ORADUR® -Oxycodone)

Product Overview

Based on DURECT's ORADUR technology, REMOXY ER is a unique long-acting formulation of oxycodone designed to discourage common methods of tampering associated with opioid misuse and abuse. It is intended for patients with moderate-to-severe chronic pain.

When taken as prescribed, opioid analgesics allows individuals suffering from chronic pain to sufficiently control their pain and resume many of their daily activities. However, this class of drugs may be abused, misused, and diverted, which has led to a major public healthcare crisis.

Potential Benefits



Commercial Opportunity



Chronic pain affects as many as 100 million Americans annually. When chronic pain is severe enough, patients are frequently prescribed long-acting opioid analgesics. Opioids (also called narcotics) include oxycodone, hydrocodone, hydromorphone, oxymorphone, morphine, fentanyl, methadone, and other members of this class. OxyContin®, a brand name oral extended-release oxycodone-based painkiller, accounted for approximately \$2.4 billion in worldwide sales in 2014.

Current Status



Commercial Rights



[Explore REMOXY ER publications >](#)

[Learn more about ORADUR abuse-deterrent technology >](#)

There are risks and uncertainties associated with our business. Please see our most recent SEC filings (10-K or 10-Q) for a complete description of these risks and uncertainties, which are incorporated herein by reference.





PRODUCTS



IN DEVELOPMENT >

DUR-928

POSIMIR® (SABER®-
Bupivacaine)

REMOXY® ER (ORADUR®-
Oxycodone)

ORADUR®-Hydromorphone and
ORADUR®-Oxymorphone

ORADUR®-Methylphenidate

RELDAY® (SABER®-Risperidone)

ELADUR® (TRANSDUR®-
Bupivacaine)

SUSTAINED-RELEASE
Ophthalmology Product

COMMERCIAL PRODUCTS

ALZET® Osmotic Pumps

LACTEL® Absorbable Polymers

REMOXY® ER (ORADUR®-Oxycodone)

Product Overview

Based on DURECT's ORADUR technology, REMOXY ER is a unique long-acting formulation of oxycodone designed to discourage common methods of tampering associated with opioid misuse and abuse. It is intended for patients with moderate-to-severe chronic pain.

When taken as prescribed, opioid analgesics allows individuals suffering from chronic pain to sufficiently control their pain and resume many of their daily activities. However, this class of drugs may be abused, misused, and diverted, which has led to a major public healthcare crisis.

Potential Benefits



Commercial Opportunity



Current Status



In March 2016, Pain Therapeutics resubmitted the NDA for REMOXY ER. In April 2016, the FDA deemed the NDA sufficiently complete to permit a substantive review, and stated that September 25, 2016 would be the target action date under the Prescription Drug User Fee Act (PDUFA).

Commercial Rights



[Explore REMOXY ER publications >](#)


[Learn more about ORADUR abuse-deterrent technology >](#)

There are risks and uncertainties associated with our business. Please see our most recent SEC filings (10-K or 10-Q) for a complete description of these risks and uncertainties, which are incorporated herein by reference.





PRODUCTS



IN DEVELOPMENT >

DUR-928

POSIMIR® (SABER®-
Bupivacaine)

REMOXY® ER (ORADUR®-
Oxycodone)

ORADUR®-Hydromorphone and
ORADUR®-Oxymorphone

ORADUR®-Methylphenidate

RELDAY® (SABER®-Risperidone)

ELADUR® (TRANSDUR®-
Bupivacaine)

SUSTAINED-RELEASE
Ophthalmology Product

COMMERCIAL PRODUCTS

ALZET® Osmotic Pumps

LACTEL® Absorbable Polymers

REMOXY® ER (ORADUR® -Oxycodone)

Product Overview

Based on DURECT's ORADUR technology, REMOXY ER is a unique long-acting formulation of oxycodone designed to discourage common methods of tampering associated with opioid misuse and abuse. It is intended for patients with moderate-to-severe chronic pain.

When taken as prescribed, opioid analgesics allows individuals suffering from chronic pain to sufficiently control their pain and resume many of their daily activities. However, this class of drugs may be abused, misused, and diverted, which has led to a major public healthcare crisis.

Potential Benefits



Commercial Opportunity



Current Status



Commercial Rights



DURECT has licensed the worldwide development and commercialization rights to Pain Therapeutics, Inc. For a description of the associated terms, please see [Collaborations](#).

[Explore REMOXY ER publications >](#)

[Learn more about ORADUR abuse-deterrent technology >](#)

There are risks and uncertainties associated with our business. Please see our most recent SEC filings (10-K or 10-Q) for a complete description of these risks and uncertainties, which are incorporated herein by reference.





Pain Therapeutics, Inc.



Contact



News



Pipeline



Investors



About Us

- [Home](#)
- [Top Stories](#)
- [Publications](#)
- [Posters](#)

NASDAQ: PTIE

Current Price: \$2.36

Change: 0.00

minimum 20 min delay

REMOXY™

Our lead drug candidate is called REMOXY® (oxycodone) Extended-Release Capsules CII. REMOXY is a strong painkiller with a unique formulation designed to reduce potential risks of unintended use.

Remoxy is intended to meet the needs of physicians who appropriately prescribe opioid painkillers and who seek to minimize risks of drug diversion, abuse or accidental patient misuse. Remoxy resists injection or snorting. Published data also show that freezing, crushing or submerging Remoxy in high-proof alcohol for hours at a time releases just a fraction of oxycodone at time points when abusers presumably expect to get high.

COPYRIGHT © 2002–2014 / PAIN THERAPEUTICS, INC. / ALL RIGHTS RESERVED / 7801 N CAPITAL OF TEXAS HWY SUITE 260 / AUSTIN, TX 78731 / PHONE: 512-501-2444 / FAX: 512-501-0414 [DISCLAIMER](#)